Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Spatial and Temporal Patterns of Typhoid and Paratyphoid Fever Outbreaks: A Worldwide Review, 1990-2018.

Kim S, Lee KS, Pak GD, Excler JL, Sahastrabuddhe S, Marks F, Kim JH, Mogasale V.

Clin Infect Dis. 2019 Oct 30;69(Supplement_6):S499-S509. doi: 10.1093/cid/ciz705.

2.

Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report.

Capeding MR, Alberto E, Sil A, Saluja T, Teshome S, Kim DR, Park JY, Yang JS, Chinaworapong S, Park J, Jo SK, Chon Y, Yang SY, Ham DS, Ryu JH, Lynch J, Kim JH, Kim H, Excler JL, Wartel TA, Sahastrabuddhe S.

Vaccine. 2019 Oct 1. pii: S0264-410X(19)31302-7. doi: 10.1016/j.vaccine.2019.09.074. [Epub ahead of print]

3.

An overview of VaxchoraTM, a live attenuated oral cholera vaccine.

Saluja T, Mogasale VV, Excler JL, Kim JH, Mogasale V.

Hum Vaccin Immunother. 2019 Sep 20:1-9. doi: 10.1080/21645515.2019.1644882. [Epub ahead of print]

PMID:
31339792
4.

Novel prime-boost vaccine strategies against HIV-1.

Excler JL, Kim JH.

Expert Rev Vaccines. 2019 Aug;18(8):765-779. doi: 10.1080/14760584.2019.1640117. Epub 2019 Jul 9.

PMID:
31271322
5.

Safety of a bivalent, killed, whole-cell oral cholera vaccine in pregnant women in Bangladesh: evidence from a randomized placebo-controlled trial.

Khan AI, Ali M, Lynch J, Kabir A, Excler JL, Khan MA, Islam MT, Akter A, Chowdhury F, Saha A, Khan IA, Desai SN, Kim DR, Saha NC, Singh AP, Clemens JD, Qadri F.

BMC Infect Dis. 2019 May 15;19(1):422. doi: 10.1186/s12879-019-4006-3.

6.

Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine.

Medise BE, Soedjatmiko S, Rengganis I, Gunardi H, Sekartini R, Koesno S, Satari HI, Hadinegoro SR, Yang JS, Excler JL, Sahastrabuddhe S, Puspita M, Sari RM, Bachtiar NS.

PLoS One. 2019 Feb 13;14(2):e0211784. doi: 10.1371/journal.pone.0211784. eCollection 2019.

7.

The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics.

Vekemans J, Gouvea-Reis F, Kim JH, Excler JL, Smeesters PR, O'Brien KL, Van Beneden CA, Steer AC, Carapetis JR, Kaslow DC.

Clin Infect Dis. 2019 Aug 16;69(5):877-883. doi: 10.1093/cid/ciy1143.

8.

Molecular epidemiology of a primarily MSM acute HIV-1 cohort in Bangkok, Thailand and connections within networks of transmission in Asia.

Chang D, Sanders-Buell E, Bose M, O'Sullivan AM, Pham P, Kroon E, Colby DJ, Sirijatuphat R, Billings E, Pinyakorn S, Chomchey N, Rutvisuttinunt W, Kijak G, de Souza M, Excler JL, Phanuphak P, Phanuphak N, O'Connell RJ, Kim JH, Robb ML, Michael NL, Ananworanich J, Tovanabutra S; RV254/SEARCH 010 Study Group.

J Int AIDS Soc. 2018 Nov;21(11):e25204. doi: 10.1002/jia2.25204.

9.

Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines.

Kochhar S, Excler JL, Bok K, Gurwith M, McNeil MM, Seligman SJ, Khuri-Bulos N, Klug B, Laderoute M, Robertson JS, Singh V, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Vaccine. 2019 Sep 10;37(38):5796-5802. doi: 10.1016/j.vaccine.2018.08.085. Epub 2018 Nov 26.

10.

The US Military Commitment to Vaccine Development: A Century of Successes and Challenges.

Ratto-Kim S, Yoon IK, Paris RM, Excler JL, Kim JH, O'Connell RJ.

Front Immunol. 2018 Jun 21;9:1397. doi: 10.3389/fimmu.2018.01397. eCollection 2018. Review.

11.

A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines.

Russo P, Ligsay AD, Olveda R, Choi SK, Kim DR, Park JY, Park JY, Syed KA, Dey A, Kim YH, Lee SH, Kim J, Chon Y, Digilio L, Kim CW, Excler JL.

Vaccine. 2018 Jul 5;36(29):4317-4324. doi: 10.1016/j.vaccine.2018.05.102. Epub 2018 Jun 9.

12.

Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children.

Capeding MR, Teshome S, Saluja T, Syed KA, Kim DR, Park JY, Yang JS, Kim YH, Park J, Jo SK, Chon Y, Kothari S, Yang SY, Ham DS, Ryu JH, Hwang HS, Mun JH, Lynch JA, Kim JH, Kim H, Excler JL, Sahastrabuddhe S.

Vaccine. 2018 Jun 18;36(26):3794-3801. doi: 10.1016/j.vaccine.2018.05.038.

13.

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.

Akapirat S, Karnasuta C, Vasan S, Rerks-Ngarm S, Pitisuttithum P, Madnote S, Savadsuk H, Rittiroongrad S, Puangkaew J, Phogat S, Tartaglia J, Sinangil F, de Souza MS, Excler JL, Kim JH, Robb ML, Michael NL, Ngauy V, O'Connell RJ, Karasavvas N; RV305 Study Group.

PLoS One. 2018 Apr 27;13(4):e0196397. doi: 10.1371/journal.pone.0196397. eCollection 2018.

14.

Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trial.

Qadri F, Ali M, Lynch J, Chowdhury F, Khan AI, Wierzba TF, Excler JL, Saha A, Islam MT, Begum YA, Bhuiyan TR, Khanam F, Chowdhury MI, Khan IA, Kabir A, Riaz BK, Akter A, Khan A, Asaduzzaman M, Kim DR, Siddik AU, Saha NC, Cravioto A, Singh AP, Clemens JD.

Lancet Infect Dis. 2018 Jun;18(6):666-674. doi: 10.1016/S1473-3099(18)30108-7. Epub 2018 Mar 14.

15.

Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges.

Cho H, Excler JL, Kim JH, Yoon IK.

Hum Vaccin Immunother. 2018 Feb 1;14(2):304-313. doi: 10.1080/21645515.2017.1389362. Epub 2017 Nov 29. Review.

16.

Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women.

Gilbert PB, Excler JL, Tomaras GD, Carpp LN, Haynes BF, Liao HX, Montefiori DC, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Kijak GH, Tovanabutra S, Francis DP, Lee C, Sinangil F, Berman PW, Premsri N, Kunasol P, O'Connell RJ, Michael NL, Robb ML, Morrow R, Corey L, Kim JH.

PLoS One. 2017 May 11;12(5):e0176428. doi: 10.1371/journal.pone.0176428. eCollection 2017.

17.

Lessons learnt from 12 oral cholera vaccine campaigns in resource-poor settings.

Hsiao A, Desai SN, Mogasale V, Excler JL, Digilio L.

Bull World Health Organ. 2017 Apr 1;95(4):303-312. doi: 10.2471/BLT.16.175166. Epub 2017 Feb 21.

18.

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.

Rerks-Ngarm S, Pitisuttithum P, Excler JL, Nitayaphan S, Kaewkungwal J, Premsri N, Kunasol P, Karasavvas N, Schuetz A, Ngauy V, Sinangil F, Dawson P, deCamp AC, Phogat S, Garunathan S, Tartaglia J, DiazGranados C, Ratto-Kim S, Pegu P, Eller M, Karnasuta C, Montefiori DC, Sawant S, Vandergrift N, Wills S, Tomaras GD, Robb ML, Michael NL, Kim JH, Vasan S, O'Connell RJ; RV305 Study Team.

J Infect Dis. 2017 Apr 15;215(8):1255-1263. doi: 10.1093/infdis/jix099.

19.

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.

Easterhoff D, Moody MA, Fera D, Cheng H, Ackerman M, Wiehe K, Saunders KO, Pollara J, Vandergrift N, Parks R, Kim J, Michael NL, O'Connell RJ, Excler JL, Robb ML, Vasan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Sinangil F, Tartaglia J, Phogat S, Kepler TB, Alam SM, Liao HX, Ferrari G, Seaman MS, Montefiori DC, Tomaras GD, Harrison SC, Haynes BF.

PLoS Pathog. 2017 Feb 24;13(2):e1006182. doi: 10.1371/journal.ppat.1006182. eCollection 2017 Feb.

20.

First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.

Nyombayire J, Anzala O, Gazzard B, Karita E, Bergin P, Hayes P, Kopycinski J, Omosa-Manyonyi G, Jackson A, Bizimana J, Farah B, Sayeed E, Parks CL, Inoue M, Hironaka T, Hara H, Shu T, Matano T, Dally L, Barin B, Park H, Gilmour J, Lombardo A, Excler JL, Fast P, Laufer DS, Cox JH; S001 Study Team.

J Infect Dis. 2017 Jan 1;215(1):95-104. doi: 10.1093/infdis/jiw500. Epub 2016 Oct 17.

21.

Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens.

Karnasuta C, Akapirat S, Madnote S, Savadsuk H, Puangkaew J, Rittiroongrad S, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Tartaglia J, Sinangil F, Francis DP, Robb ML, de Souza MS, Michael NL, Excler JL, Kim JH, O'Connell RJ, Karasavvas N.

AIDS Res Hum Retroviruses. 2017 May;33(5):410-423. doi: 10.1089/AID.2016.0204. Epub 2017 Jan 30.

22.

Lessons from HIV-1 vaccine efficacy trials.

Excler JL, Michael NL.

Curr Opin HIV AIDS. 2016 Nov;11(6):607-613. Review.

PMID:
27537673
23.

Accelerating the development of a group A Streptococcus vaccine: an urgent public health need.

Excler JL, Kim JH.

Clin Exp Vaccine Res. 2016 Jul;5(2):101-7. doi: 10.7774/cevr.2016.5.2.101. Epub 2016 Jul 29. Review.

24.

Toward Developing a Preventive MERS-CoV Vaccine-Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14-15, 2015.

Excler JL, Delvecchio CJ, Wiley RE, Williams M, Yoon IK, Modjarrad K, Boujelal M, Moorthy VS, Hersi AS, Kim JH; MERS-CoV Vaccine Working Group.

Emerg Infect Dis. 2016 Aug;22(8). doi: 10.3201/eid2208.160229.

25.

Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains.

Condit RC, Williamson AL, Sheets R, Seligman SJ, Monath TP, Excler JL, Gurwith M, Bok K, Robertson JS, Kim D, Michael Hendry R, Singh V, Mac LM, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Vaccine. 2016 Dec 12;34(51):6610-6616. doi: 10.1016/j.vaccine.2016.04.060. Epub 2016 Jun 23. Review.

26.

Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.

O'Connell RJ, Excler JL, Polonis VR, Ratto-Kim S, Cox J, Jagodzinski LL, Liu M, Wieczorek L, McNeil JG, El-Habib R, Michael NL, Gilliam BL, Paris R, VanCott TC, Tomaras GD, Birx DL, Robb ML, Kim JH.

J Infect Dis. 2016 Jun 15;213(12):1946-54. doi: 10.1093/infdis/jiw059. Epub 2016 Feb 11.

27.

HIV prevention & treatment--reasons to rejoice & remain vigilant.

Excler JL.

Indian J Med Res. 2015 Dec;142(6):633-6. doi: 10.4103/0971-5916.174534. No abstract available.

28.

Prospects for a Globally Effective HIV-1 Vaccine.

Excler JL, Robb ML, Kim JH.

Am J Prev Med. 2015 Dec;49(6 Suppl 4):S307-18. doi: 10.1016/j.amepre.2015.09.004. Review.

PMID:
26590431
29.

New prospects for a preventive HIV-1 vaccine.

Brown J, Excler JL, Kim JH.

J Virus Erad. 2015 Apr;1(2):78-88.

30.

IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens.

Karasavvas N, Karnasuta C, Savadsuk H, Madnote S, Inthawong D, Chantakulkij S, Rittiroongrad S, Nitayaphan S, Pitisuttithum P, Thongcharoen P, Siriyanon V, Andrews CA, Barnett SW, Tartaglia J, Sinangil F, Francis DP, Robb ML, Michael NL, Ngauy V, de Souza MS, Paris RM, Excler JL, Kim JH, O'Connell RJ; MOPH-TAVEG Collaboration.

AIDS Res Hum Retroviruses. 2015 Nov;31(11):1178-86. doi: 10.1089/AID.2015.0034. Epub 2015 Sep 9.

31.

HIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials.

Phanuphak N, Lo YR, Shao Y, Solomon SS, O'Connell RJ, Tovanabutra S, Chang D, Kim JH, Excler JL.

AIDS Res Hum Retroviruses. 2015 Nov;31(11):1060-76. doi: 10.1089/aid.2015.0049. Epub 2015 Jun 24. Review.

32.

Prospects for a globally effective HIV-1 vaccine.

Excler JL, Robb ML, Kim JH.

Vaccine. 2015 Nov 27;33 Suppl 4:D4-12. doi: 10.1016/j.vaccine.2015.03.059. Epub 2015 Jun 20. Review.

PMID:
26100921
33.

Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward.

Lo YR, Chu C, Ananworanich J, Excler JL, Tucker JD.

AIDS Patient Care STDS. 2015 Jul;29(7):389-99. doi: 10.1089/apc.2014.0348. Epub 2015 May 18. Review.

34.

Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand.

Pitisuttithum P, Rerks-Ngarm S, Stablein D, Dawson P, Nitayaphan S, Kaewkungwal J, Michael NL, Kim JH, Robb ML, O'Connell RJ, Yoon IK, Fernandez S, Excler JL.

PLoS One. 2015 May 26;10(5):e0127998. doi: 10.1371/journal.pone.0127998. eCollection 2015.

35.

Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection.

Vasan S, Rerks-Ngarm S, Gilbert P, Haynes B, Nitayapan S, Pitisuttihum P, Kaewkungwal J, Excler JL, Robb M, Michael N, Kim J, O'Connell R.

Hum Vaccin Immunother. 2015;11(4):1036-7. doi: 10.1080/21645515.2015.1010970. No abstract available.

36.

Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation.

Schuetz A, Deleage C, Sereti I, Rerknimitr R, Phanuphak N, Phuang-Ngern Y, Estes JD, Sandler NG, Sukhumvittaya S, Marovich M, Jongrakthaitae S, Akapirat S, Fletscher JL, Kroon E, Dewar R, Trichavaroj R, Chomchey N, Douek DC, O Connell RJ, Ngauy V, Robb ML, Phanuphak P, Michael NL, Excler JL, Kim JH, de Souza MS, Ananworanich J; RV254/SEARCH 010 and RV304/SEARCH 013 Study Groups.

PLoS Pathog. 2014 Dec 11;10(12):e1004543. doi: 10.1371/journal.ppat.1004543. eCollection 2014 Dec.

37.

Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment.

Monath TP, Seligman SJ, Robertson JS, Guy B, Hayes EB, Condit RC, Excler JL, Mac LM, Carbery B, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Vaccine. 2015 Jan 1;33(1):62-72. doi: 10.1016/j.vaccine.2014.10.004. Epub 2014 Oct 27. Review.

38.

Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection.

Kim JH, Excler JL, Michael NL.

Annu Rev Med. 2015;66:423-37. doi: 10.1146/annurev-med-052912-123749. Epub 2014 Oct 17. Review.

PMID:
25341006
39.

The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Chen RT, Carbery B, Mac L, Berns KI, Chapman L, Condit RC, Excler JL, Gurwith M, Hendry M, Khan AS, Khuri-Bulos N, Klug B, Robertson JS, Seligman SJ, Sheets R, Williamson AL; V3SWG.

Vaccine. 2015 Jan 1;33(1):73-5. doi: 10.1016/j.vaccine.2014.09.035. Epub 2014 Oct 8.

40.

The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.

O'Connell RJ, Kim JH, Excler JL.

Expert Rev Vaccines. 2014 Dec;13(12):1489-500. doi: 10.1586/14760584.2014.951335. Epub 2014 Aug 28. Review.

PMID:
25163695
41.

Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.

Excler JL, Ake J, Robb ML, Kim JH, Plotkin SA.

Clin Vaccine Immunol. 2014 Aug;21(8):1023-36. doi: 10.1128/CVI.00230-14. Epub 2014 Jun 11. Review.

42.

Expectation of volunteers towards the vaccine efficacy of the prime-boost HIV vaccine phase III trial during unblinding.

Khowsroy K, Dhitavat J, Sabmee Y, Laowarakul P, Wattanakitwichai J, Auetian J, Lothong K, Boondao R, Maythaarttaphong S, Yaemwong S, Excler JL, Rerks-Ngarm S, Pitisuttithum P.

AIDS Res Hum Retroviruses. 2014 Nov;30(11):1041-5. doi: 10.1089/AID.2013.0136. Epub 2014 Jul 8.

43.

HIV-1 vaccines: challenges and new perspectives.

Excler JL, Robb ML, Kim JH.

Hum Vaccin Immunother. 2014;10(6):1734-46. doi: 10.4161/hv.28462. Epub 2014 Mar 17. Review.

44.

Broad HIV epitope specificity and viral inhibition induced by multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.

Kopycinski J, Hayes P, Ashraf A, Cheeseman H, Lala F, Czyzewska-Khan J, Spentzou A, Gill DK, Keefer MC, Excler JL, Fast P, Cox J, Gilmour J.

PLoS One. 2014 Mar 7;9(3):e90378. doi: 10.1371/journal.pone.0090378. eCollection 2014.

45.

HIV vaccine efficacy and immune correlates of risk.

O'Connell RJ, Excler JL.

Curr HIV Res. 2013 Sep;11(6):450-63. Review.

PMID:
24033301
46.

Novel directions in HIV-1 vaccines revealed from clinical trials.

Excler JL, Tomaras GD, Russell ND.

Curr Opin HIV AIDS. 2013 Sep;8(5):421-31. doi: 10.1097/COH.0b013e3283632c26. Review.

47.

Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers.

Mehendale S, Thakar M, Sahay S, Kumar M, Shete A, Sathyamurthi P, Verma A, Kurle S, Shrotri A, Gilmour J, Goyal R, Dally L, Sayeed E, Zachariah D, Ackland J, Kochhar S, Cox JH, Excler JL, Kumaraswami V, Paranjape R, Ramanathan VD.

PLoS One. 2013;8(2):e55831. doi: 10.1371/journal.pone.0055831. Epub 2013 Feb 13.

48.

An HIV Vaccine for South-East Asia-Opportunities and Challenges.

Pitisuttithum P, Rerks-Ngarm S, O'Connell RJ, Kim JH, Excler JL.

Vaccines (Basel). 2013 Aug 14;1(3):348-66. doi: 10.3390/vaccines1030348.

49.

Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.

Ratto-Kim S, Currier JR, Cox JH, Excler JL, Valencia-Micolta A, Thelian D, Lo V, Sayeed E, Polonis VR, Earl PL, Moss B, Robb ML, Michael NL, Kim JH, Marovich MA.

PLoS One. 2012;7(9):e45840. doi: 10.1371/journal.pone.0045840. Epub 2012 Sep 26.

50.

HIV epidemic in Asia: optimizing and expanding vaccine development.

Nitayaphan S, Ngauy V, O'Connell R, Excler JL.

Expert Rev Vaccines. 2012 Jul;11(7):805-19. doi: 10.1586/erv.12.49. Review.

PMID:
22913258

Supplemental Content

Loading ...
Support Center